法尼醇X受体在非酒精性脂肪性肝病中的最新研究进展
Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
作者信息
Xu Jiao-Ya, Li Zhong-Ping, Zhang Li, Ji Guang
机构信息
Jiao-Ya Xu, Zhong-Ping Li, Li Zhang, Guang Ji, Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
出版信息
World J Gastroenterol. 2014 Oct 7;20(37):13493-500. doi: 10.3748/wjg.v20.i37.13493.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is one of the most prevalent liver disorders worldwide. NAFLD can gradually progress to liver inflammation, fibrosis, cirrhosis and even hepatocellular carcinoma. However, the pathogenesis of NAFLD is complex, and no efficient pharmaceutic treatments have yet been established for NAFLD. Accumulating data have shown that the farnesoid X receptor (FXR) plays important roles not only in bile acid metabolism, but also in lipid and carbohydrate homeostasis, inflammatory responses, among others. In this review, we aim to highlight the role of FXR in the pathogenesis and treatment of NAFLD.
摘要
非酒精性脂肪性肝病（NAFLD）是代谢综合征的肝脏表现，也是全球最常见的肝脏疾病之一。NAFLD可逐渐发展为肝脏炎症、纤维化、肝硬化甚至肝细胞癌。然而，NAFLD的发病机制复杂，目前尚未建立有效的药物治疗方法。越来越多的数据表明，法尼醇X受体（FXR）不仅在胆汁酸代谢中起重要作用，而且在脂质和碳水化合物稳态、炎症反应等方面也发挥重要作用。在本综述中，我们旨在强调FXR在NAFLD发病机制和治疗中的作用。
相似文献
1
Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.法尼醇X受体在非酒精性脂肪性肝病中的最新研究进展
World J Gastroenterol. 2014 Oct 7;20(37):13493-500. doi: 10.3748/wjg.v20.i37.13493.
2
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.胆汁酸在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
Mol Aspects Med. 2017 Aug;56:34-44. doi: 10.1016/j.mam.2017.04.004. Epub 2017 May 5.
3
FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.法尼酯X受体激动剂作为非酒精性脂肪性肝病的治疗药物。
Curr Atheroscler Rep. 2015 Apr;17(4):500. doi: 10.1007/s11883-015-0500-2.
4
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.法尼醇X受体在非酒精性脂肪性肝炎中胆汁酸和代谢稳态中的作用：发病机制概念与治疗机会
Semin Liver Dis. 2021 Nov;41(4):461-475. doi: 10.1055/s-0041-1731707. Epub 2021 Jul 21.
5
Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.用于治疗非酒精性脂肪性肝病的核受体调节
Semin Liver Dis. 2016 Feb;36(1):69-86. doi: 10.1055/s-0036-1571296. Epub 2016 Feb 12.
6
Role of FXR in the development of NAFLD and intervention strategies of small molecules.FXR 在非酒精性脂肪性肝病（NAFLD）发展中的作用及其小分子干预策略。
Arch Biochem Biophys. 2024 Jul;757:110024. doi: 10.1016/j.abb.2024.110024. Epub 2024 May 3.
7
Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment.针对非酒精性脂肪性肝炎 (NASH) 治疗中琥珀酸-GPR91 信号通路药物候选物的展望。
Biomed Pharmacother. 2021 Dec;144:112298. doi: 10.1016/j.biopha.2021.112298. Epub 2021 Oct 12.
8
Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances.胆汁酸在非酒精性脂肪性肝病中的作用：新概念和治疗进展。
Ann Hepatol. 2017 Nov;16(Suppl. 1: s3-105.):s58-s67. doi: 10.5604/01.3001.0010.5498.
9
Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.司维拉姆改善非酒精性脂肪性肝病小鼠模型中的脂肪性肝炎，抑制肝脏和肠道法尼醇X受体（FXR），并逆转先天免疫失调。
J Biol Chem. 2016 Oct 28;291(44):23058-23067. doi: 10.1074/jbc.M116.731042. Epub 2016 Sep 7.
10
A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development.当前对 FXR 在非酒精性脂肪性肝病中的认识：FXR 的多方面调节作用及药物研发的新型先导化合物发现。
Biomed Pharmacother. 2024 Jun;175:116658. doi: 10.1016/j.biopha.2024.116658. Epub 2024 May 2.
引用本文的文献
1
Liver immunology: Biological role and clinical significance.肝脏免疫学：生物学作用及临床意义。
World J Hepatol. 2025 Jul 27;17(7):107541. doi: 10.4254/wjh.v17.i7.107541.
2
From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.从病理生理学到临床实践：门静脉高压症不断发展的药物治疗、临床并发症及药物遗传学考量
Metabolites. 2025 Jan 23;15(2):72. doi: 10.3390/metabo15020072.
3
Farnesoid X receptor: From Structure to Function and Its Pharmacology in Liver Fibrosis.法尼醇 X 受体：从结构到功能及其在肝纤维化中的药理学。
Aging Dis. 2024 Aug 1;15(4):1508-1536. doi: 10.14336/AD.2023.0830.
4
Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXR.肝脏中的Clstn3通过激活法尼醇X受体（FXR）改善高脂饮食诱导的非酒精性脂肪性肝病（NAFLD）中的脂质代谢紊乱。
ACS Omega. 2023 Jul 12;8(29):26158-26169. doi: 10.1021/acsomega.3c02347. eCollection 2023 Jul 25.
5
Therapeutic targets in alcohol-associated liver disease: progress and challenges.酒精性肝病的治疗靶点：进展与挑战
Therap Adv Gastroenterol. 2023 May 10;16:17562848231170946. doi: 10.1177/17562848231170946. eCollection 2023.
6
EDP-297: A novel, farnesoid X receptor agonist-Results of a phase I study in healthy subjects.EDP-297：一种新型法尼醇 X 受体激动剂——在健康受试者中进行的 I 期研究结果。
Clin Transl Sci. 2023 Feb;16(2):338-351. doi: 10.1111/cts.13453. Epub 2022 Nov 21.
7
Cholesterol metabolism in aging simultaneously altered in liver and nervous system.衰老过程中肝脏和神经系统中的胆固醇代谢同时发生改变。
Aging (Albany NY). 2022 Feb 7;14(3):1549-1561. doi: 10.18632/aging.203880.
8
Emerging medical therapies for severe alcoholic hepatitis.治疗严重酒精性肝炎的新兴医学疗法。
Clin Mol Hepatol. 2020 Oct;26(4):686-696. doi: 10.3350/cmh.2020.0145. Epub 2020 Sep 28.
9
Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism.胆酸介导的 FXR 和 FATP5 之间在脂质代谢调节中的潜在功能相互作用。
Int J Biol Sci. 2020 Jun 14;16(13):2308-2322. doi: 10.7150/ijbs.44774. eCollection 2020.
10
Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH).针对分泌蛋白的治疗策略在非酒精性脂肪性肝炎（NASH）治疗中的应用。
Int J Mol Sci. 2020 Mar 26;21(7):2296. doi: 10.3390/ijms21072296.
本文引用的文献
1
SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes.固醇调节元件结合蛋白1c（SREBP-1c）的过表达通过增加脂质合成、减少脂质氧化以及极低密度脂蛋白（VLDL）组装，诱导牛肝细胞内甘油三酯蓄积。
J Steroid Biochem Mol Biol. 2014 Sep;143:174-82. doi: 10.1016/j.jsbmb.2014.02.009. Epub 2014 Feb 22.
2
Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus.非酒精性脂肪性肝病与2型糖尿病患者的主动脉瓣硬化有关。
PLoS One. 2014 Feb 5;9(2):e88371. doi: 10.1371/journal.pone.0088371. eCollection 2014.
3
[Effects of farnesoid X receptor agonist on adiponectin and its receptors].法尼酯X受体激动剂对脂联素及其受体的影响
Nan Fang Yi Ke Da Xue Xue Bao. 2014 Jan;34(1):109-12.
4
Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study.非酒精性脂肪性肝病患者患结直肠恶性肿瘤的风险增加：一项大型研究。
Mol Biol Rep. 2014 May;41(5):2989-97. doi: 10.1007/s11033-014-3157-y. Epub 2014 Jan 22.
5
Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.非酒精性脂肪性肝炎是美国肝细胞癌患者进行肝移植的增长最快的指征。
Hepatology. 2014 Jun;59(6):2188-95. doi: 10.1002/hep.26986. Epub 2014 Apr 25.
6
Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice.衰老小鼠内质网应激介导的 FXR 下调加剧肝脂肪变性。
J Hepatol. 2014 Apr;60(4):847-54. doi: 10.1016/j.jhep.2013.12.003. Epub 2013 Dec 11.
7
Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments.系统评价与荟萃分析：非酒精性脂肪性肝病的无创性评估——瞬时弹性成像和血浆细胞角蛋白 18 片段的作用。
Aliment Pharmacol Ther. 2014 Feb;39(3):254-69. doi: 10.1111/apt.12569. Epub 2013 Dec 5.
8
Activation of farnesoid X receptor induces RECK expression in mouse liver.法尼醇 X 受体的激活诱导小鼠肝脏中 REck 的表达。
Biochem Biophys Res Commun. 2014 Jan 3;443(1):211-6. doi: 10.1016/j.bbrc.2013.11.082. Epub 2013 Nov 28.
9
Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.法尼醇 X 受体的激活可减轻酒精性肝病小鼠模型中的肝损伤。
Biochem Biophys Res Commun. 2014 Jan 3;443(1):68-73. doi: 10.1016/j.bbrc.2013.11.057. Epub 2013 Nov 20.
10
Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events.非酒精性脂肪性肝病与心血管及肾脏事件发生率之间的关联。
J Saudi Heart Assoc. 2013 Oct;25(4):239-46. doi: 10.1016/j.jsha.2013.07.004.
Zotero 插件